DK1545599T3 - Immunogene præparater og diagnostiske og terapeutiske anvendelser deraf - Google Patents

Immunogene præparater og diagnostiske og terapeutiske anvendelser deraf Download PDF

Info

Publication number
DK1545599T3
DK1545599T3 DK03737755.3T DK03737755T DK1545599T3 DK 1545599 T3 DK1545599 T3 DK 1545599T3 DK 03737755 T DK03737755 T DK 03737755T DK 1545599 T3 DK1545599 T3 DK 1545599T3
Authority
DK
Denmark
Prior art keywords
gpi
inositol
domain
plasmodium
parasite
Prior art date
Application number
DK03737755.3T
Other languages
English (en)
Inventor
Louis Schofield
Original Assignee
Inst Medical W & E Hall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Medical W & E Hall filed Critical Inst Medical W & E Hall
Application granted granted Critical
Publication of DK1545599T3 publication Critical patent/DK1545599T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Claims (19)

1. Immunogent præparat, der omfatter inositolglycan- domænedelen af en parasit-GPI, hvilken inositolglycan- domænedel omfatter utilstrækkeligt lipiddomæne til at inducere eller fremkalde en immunrespons rettet mod et GPI-lipiddomæne, og som har en terminal inositolphosphoglycerol, der er substitueret med inositol-1,2-cyklisk phosphat, til anvendelse til behandling og/eller profylakse af en parasitinfektion hos et pattedyr, hvor parasitten er Plasmodium.
2. Præparat til anvendelse ifølge krav 1, hvor Plasmodium er Plasmodium falciparum.
3. Præparat til anvendelse ifølge et hvilket som helst af kravene 1 eller 2, hvor GPI-molekylet er et Plasmodium falciparum-GPI-inositolglycandomæne.
4. Præparat til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor GPI-inositolglycandomænet omfatter strukturen: EtN-P-(Manal, 2)-6Mal,2Mal,6Manal,4GlcNH2al-myo-inositol-l,2-cyklisk phosphat, hvor EtN er ethanolamin, P er phosphat, og M er mannose.
5. Præparat til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor GPI-inositolglycandomænet omfatter strukturen: NH2-CH2-CH2-PO4- (Manal-2) -6Manal-2Manal-6Manal-4GlcNH2-6myo-inositol-1,2-cyklisk phosphat.
6. Immunogent præparat til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor parasitinfektionen er malaria.
7. Farmaceutisk præparat, der omfatter en parasit-GPI- inositolglycan-domænedel, men hvilken del er i det væsentlige ude af stand til at inducere en immunrespons rettet mod et lipiddomæne af en GPI, og som har en terminal inositolphosphoglycerol, der er substitueret med inositol-1,2-cyklisk phosphat, sammen med et eller flere farmaceutisk acceptable bærematerialer og/eller fortyndingsmidler, hvor parasitten er Plasmodium.
8. Præparat ifølge krav 7, som er et vaccinepræparat til inducering af en immunrespons mod en parasit, hvor parasitten er Plasmodium.
9. Præparat ifølge krav 8, hvor Plasmodium er Plasmodium falciparum.
10. Præparat ifølge krav 8, hvor GPI-molekylet er Plasmodium falciparum-GPl-inositolglycandomæne.
11. Præparat ifølge et hvilket som helst af kravene 7 til 10, hvor GPI-inositolglycandomænet omfatter strukturen: EtN-P-(Manal, 2)-6Mal,2Mal,6Manal,4GlcNH2al-myo-inositol-l,2-cyklisk phosphat, hvor EtN er ethanolamin, P er phosphat, og M er mannose.
12. Præparat ifølge et hvilket som helst af kravene 7 til 10, hvor GPI-inositolglycandomænet omfatter strukturen: NH2-CH2- CH2-PO4-(Manal-2)-6Manal-2Manal-6Manal-4GlcNH2-6myo-inositol-1,2-cyklisk phosphat.
13. Fremgangsmåde til påvisning i en biologisk prøve af et immuninteraktivt molekyle rettet mod Plasmodium, hvilken fremgangsmåde omfatter etablering af kontakt mellem den biologiske prøve og et molekyle, der omfatter et derivat af GPI-inositolglycandomænet fra Plasmodium, som omfatter utilstrækkeligt lipiddomæne til at inducere eller fremkalde en immunrespons rettet mod et GPI-lipiddomæne, hvor inositolglycandomænet har en terminal inositolphosphoglycerol, der er substitueret med inositol-1,2-cyklisk phosphat, og kvalitativ og/eller kvantitativ screening for komplekdannelse mellem GPI-inositolglycandomænet og det immuninteraktive molekyle.
14. Fremgangsmåde ifølge krav 13 til påvisning, overvågning eller på anden vis vurdering af en immunrespons rettet mod Plasmodium i personen.
15. Fremgangsmåde ifølge krav 13, hvor Plasmodium er Plasmodium falciparum.
16. Fremgangsmåde ifølge krav 15, hvor det modificerede Plasmodium jfalciparum-GPI-molekyle er et Plasmodium falciparum-GPI-inositolglycandomæne.
17. Fremgangsmåde ifølge krav 16, hvor GPI- inositolglycandomænet er syntetisk og omfatter strukturen: EtN-P-(Manal, 2)-6Mal,2Mal,6Manal,4GlcNH2al-myo-inositol-l,2-cyklisk phosphat, hvor EtN er ethanolamin, P er phosphat, og M er mannose.
18. Fremgangsmåde ifølge krav 16, hvor GPI- inositolglycandomænet er syntetisk og omfatter strukturen: NH2-CH2-CH2-PO4- (Manal-2) -6Manal-2-Manal-6Manal-4GlcNH2-6myo-inositol-1,2-cyklisk phosphat.
19. Modulsæt, der omfatter en eller flere dele, hvor mindst én del er en fast understøtning, der omfatter et GPI-molekyle ifølge krav 7 .
DK03737755.3T 2002-07-26 2003-07-25 Immunogene præparater og diagnostiske og terapeutiske anvendelser deraf DK1545599T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39860702P 2002-07-26 2002-07-26
PCT/AU2003/000944 WO2004011026A1 (en) 2002-07-26 2003-07-25 Immunogenic compositions and diagnostic and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
DK1545599T3 true DK1545599T3 (da) 2015-08-03

Family

ID=31188433

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03737755.3T DK1545599T3 (da) 2002-07-26 2003-07-25 Immunogene præparater og diagnostiske og terapeutiske anvendelser deraf

Country Status (9)

Country Link
US (2) US8038986B2 (da)
EP (1) EP1545599B1 (da)
CN (1) CN1681529B (da)
AU (1) AU2003245127B2 (da)
BR (1) BR0312985A (da)
CA (1) CA2493782C (da)
DK (1) DK1545599T3 (da)
HU (1) HUE025624T2 (da)
WO (1) WO2004011026A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP589398A0 (en) * 1998-09-14 1998-10-08 Walter And Eliza Hall Institute Of Medical Research, The Immunogenic compositions and uses thereof
AU2003248927A1 (en) * 2002-07-10 2004-01-23 Massachusetts Institute Of Technology Solid-phase and solution-phase synthesis of glycosylphosphatidylinositol glycans
DK1545599T3 (da) 2002-07-26 2015-08-03 Inst Medical W & E Hall Immunogene præparater og diagnostiske og terapeutiske anvendelser deraf
JP2008501725A (ja) * 2004-06-10 2008-01-24 ザ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ グリカンに特異的な受容体として機能するインテグリンを介したグリコシルホスファチジルイノシトールグリカンシグナル伝達
GB2429013C (en) 2005-08-11 2012-11-28 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmunedisease
GB2446088B (en) * 2005-12-12 2010-10-20 Innova Biosciences Ltd Production of conjugates
WO2008014733A1 (de) * 2006-08-02 2008-02-07 Johannes Gutenberg-Universität Mainz Arzneimittel gegen lct-vergiftungen
FR2912218A1 (fr) * 2007-02-07 2008-08-08 Commissariat Energie Atomique Antigene digalactolipidique expose a la surface des parasites apicomplexes et ses applications diagnostiques et therapeutiques
EP2186818A1 (en) * 2008-11-04 2010-05-19 ETH Zurich Chemical synthesis of phosphatidylinositol mannoside glycans form mycobacterium tuberculosis
WO2012049623A1 (en) 2010-10-11 2012-04-19 Ecole Polytechnique Federale De Lausanne (Epfl) Mechanical manipulator for surgical instruments
JP5715304B2 (ja) 2011-07-27 2015-05-07 エコール ポリテクニーク フェデラル デ ローザンヌ （イーピーエフエル） 遠隔操作のための機械的遠隔操作装置
AU2012304181C1 (en) * 2011-08-30 2017-04-27 The Governors Of The University Of Alberta Method and system for ABO antibody detection and characterization
WO2015113933A1 (en) 2014-02-03 2015-08-06 Distalmotion Sa Mechanical teleoperated device comprising an interchangeable distal instrument
EP3185808B1 (en) 2014-08-27 2022-02-23 DistalMotion SA Surgical system for microsurgical techniques
EP4342412A3 (en) 2014-12-19 2024-06-05 DistalMotion SA Reusable surgical instrument for minimally invasive procedures
US10548680B2 (en) 2014-12-19 2020-02-04 Distalmotion Sa Articulated handle for mechanical telemanipulator
EP3232973B1 (en) 2014-12-19 2020-04-01 DistalMotion SA Sterile interface for articulated surgical instruments
WO2016097871A1 (en) 2014-12-19 2016-06-23 Distalmotion Sa Docking system for mechanical telemanipulator
DK3232951T3 (da) 2014-12-19 2024-01-15 Distalmotion Sa Kirurgisk instrument med leddelt ende-effektor
EP3280343A1 (en) 2015-04-09 2018-02-14 DistalMotion SA Mechanical teleoperated device for remote manipulation
WO2016162751A1 (en) 2015-04-09 2016-10-13 Distalmotion Sa Articulated hand-held instrument
US10786272B2 (en) 2015-08-28 2020-09-29 Distalmotion Sa Surgical instrument with increased actuation force
US11058503B2 (en) 2017-05-11 2021-07-13 Distalmotion Sa Translational instrument interface for surgical robot and surgical robot systems comprising the same
US10413374B2 (en) 2018-02-07 2019-09-17 Distalmotion Sa Surgical robot systems comprising robotic telemanipulators and integrated laparoscopy
JP6530846B1 (ja) * 2018-10-09 2019-06-12 アサヒグループホールディングス株式会社 免疫賦活剤及び感染予防方法
CN109825514A (zh) * 2019-01-24 2019-05-31 华中农业大学 田鼠巴贝斯虫gpi10基因及其编码的蛋白和应用
US11844585B1 (en) 2023-02-10 2023-12-19 Distalmotion Sa Surgical robotics systems and devices having a sterile restart, and methods thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4849338A (en) 1982-07-16 1989-07-18 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4843000A (en) 1979-12-26 1989-06-27 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US5227487A (en) 1990-04-16 1993-07-13 Molecular Probes, Inc. Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
US5453517A (en) 1992-02-25 1995-09-26 Molecular Probes, Inc. Reactive derivatives of bapta used to make ion-selective chelators
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5326692B1 (en) 1992-05-13 1996-04-30 Molecular Probes Inc Fluorescent microparticles with controllable enhanced stokes shift
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5648270A (en) 1995-02-06 1997-07-15 Molecular Probes, Inc. Methods of sensing with fluorescent conjugates of metal-chelating nitrogen heterocycles
US5405975A (en) 1993-03-29 1995-04-11 Molecular Probes, Inc. Fluorescent ion-selective diaryldiaza crown ether conjugates
US5723218A (en) 1990-04-16 1998-03-03 Molecular Probes, Inc. Dipyrrometheneboron difluoride labeled flourescent microparticles
US5459276A (en) 1994-05-20 1995-10-17 Molecular Probes, Inc. Benzazolylcoumarin-based ion indicators for heavy metals
AU669489B2 (en) 1991-09-18 1996-06-13 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
GB9203039D0 (en) 1992-02-13 1992-03-25 Univ London Treatment
DE4311580C1 (de) 1993-04-12 1994-08-18 Werner Prof Dr Med Reutter Glycoproteine, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Mittel
US6113917A (en) 1995-04-25 2000-09-05 Rmf Dictagene S.A. Modified polypeptides for enhanced immunogenicity
ATE221539T1 (de) 1995-09-15 2002-08-15 Organon Teknika Bv Toxoplasma gondii glykokonjugate
EP0885012A4 (en) 1996-01-29 2001-09-05 Univ Georgetown MALARIA VACCINES USING AN MSA1 PEPTIDE
US7968689B2 (en) 1997-03-07 2011-06-28 Human Genome Sciences, Inc. Antibodies to HSDEK49 polypeptides
US5968742A (en) 1997-05-22 1999-10-19 Incyte Pharmaceuticals, Inc. Human GPI2 homolog
US20070014787A1 (en) 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
AUPP589398A0 (en) 1998-09-14 1998-10-08 Walter And Eliza Hall Institute Of Medical Research, The Immunogenic compositions and uses thereof
AUPP675898A0 (en) 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of activating t cells and agents useful for same
AU2003248927A1 (en) * 2002-07-10 2004-01-23 Massachusetts Institute Of Technology Solid-phase and solution-phase synthesis of glycosylphosphatidylinositol glycans
DK1545599T3 (da) 2002-07-26 2015-08-03 Inst Medical W & E Hall Immunogene præparater og diagnostiske og terapeutiske anvendelser deraf
AU2004259727A1 (en) 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases.
JP2008501725A (ja) 2004-06-10 2008-01-24 ザ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ グリカンに特異的な受容体として機能するインテグリンを介したグリコシルホスファチジルイノシトールグリカンシグナル伝達
US7928077B2 (en) 2008-07-11 2011-04-19 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies

Also Published As

Publication number Publication date
BR0312985A (pt) 2005-06-21
EP1545599A4 (en) 2006-04-05
EP1545599B1 (en) 2015-04-29
EP1545599A1 (en) 2005-06-29
US8038986B2 (en) 2011-10-18
CN1681529B (zh) 2012-09-19
CN1681529A (zh) 2005-10-12
WO2004011026A1 (en) 2004-02-05
US20120027762A1 (en) 2012-02-02
US8501183B2 (en) 2013-08-06
AU2003245127B2 (en) 2007-11-29
US20060147476A1 (en) 2006-07-06
CA2493782A1 (en) 2004-02-05
AU2003245127A1 (en) 2004-02-16
CA2493782C (en) 2016-05-31
HUE025624T2 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
US8501183B2 (en) Immunogenic compositions and diagnostic and therapeutic uses thereof
US8058401B2 (en) Immunogenic compositions and uses thereof
Skelly et al. Making sense of the schistosome surface
CA2593643A1 (en) A plasmodium vivax hybrid circumsporozoite protein and vaccine
Wahlgren Antigens and antibodies involved in humoral immunity to Plasmodium falciparum
Joiner et al. gp72, the 72 kilodalton glycoprotein, is the membrane acceptor site for C3 on Trypanosoma cruzi epimastigotes.
US20030161838A1 (en) Isolation and purification of P. falciparum merozoite protein-142 vaccine
DK171259B1 (da) Specifikke ekskretion-sekretions antigener af Toxoplasma gondii, translatiosprodukter deraf, fremgangsmåde til fremstilling deraf og diagnostiske anvendelser deraf
EP0850244B1 (en) Toxoplasma gondii glycoconjugates
SCHOFIELD Patent 2493782 Summary
AU766837B2 (en) Immunogenic compositions and uses thereof
Avila α-Galactosyl-Bearing Epitopes as Potent Immunogens in Chagas’ Disease and Leishmaniasis
US7306806B2 (en) Recombinant P. falciparum merozoite protein-142 vaccine
CA2061507A1 (en) Immunogens derived from pathogen-free tick species or cell lines, and tick vaccines derived thereform
AU775222B2 (en) A method of activating T cells and agents useful for same
Jansen Identification of non-procyclin molecules expressed by Trypanosoma brucei brucei procyclic culture forms
US20100239614A1 (en) Isolation and Purification of P. Falciparum Merozoite Protein-142 Vaccine
Tolson The immunochemistry and immunobiology of Leishmania Donovani lipophosphoglycan